Beyond Air Inc. released its financial results for the fiscal year ending March 31, 2025. The company reported a significant increase in revenue, reaching $3.7 million compared to $1.2 million for the previous year. However, the company also reported a net loss of $48.5 million, slightly improved from the $64.3 million loss in the prior year. Operating expenses were reduced to $42.9 million from $61.7 million, driven by lower research and development and selling, general, and administrative costs. The company, a commercial-stage medical device and biopharmaceutical entity, continues to face challenges reflected in its comprehensive loss, which stood at $46.7 million, compared to $60.3 million in the previous year. No specific outlook or guidance was provided in the report.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.